Health innovators are operating in an environment where scientific progress, evidence, regulation, reimbursement, implementation, and patient access must advance together. At the Global Health and Purpose Summit, as part of People and Planet United, David Farber, Partner at King & Spalding, joins host Gil Bashe, Chair, Global Health and Purpose at FINN Partners, for a leadership conversation on Regulating Innovation: How Policy is Reshaping the Future of Health.

The discussion places CMS, FDA, CMMI, reimbursement frameworks, payer dynamics, program integrity, evidence expectations, AI-enabled care models, remote monitoring, breakthrough devices, and digital tools inside the same leadership frame. Health innovation no longer moves through a simple path from invention to adoption. It moves through a more demanding environment where new technologies must be evaluated, covered, paid for, adopted, measured, and trusted before they can reach patients at scale.

Farber’s central message is that policy is becoming part of the innovation model itself. Strong science remains essential, but it is not enough. Organizations need reimbursement strategy, payer engagement, regulatory readiness, outcomes evidence, and implementation discipline from the beginning. Bashe grounds the conversation in the everyday reality of care delivery, where smart embedded technologies, wearables, remote monitoring, and ambient tools can reduce friction and help clinicians focus more directly on patients.

Policy as Part of the Innovation Model

Healthcare companies often begin with a clinical problem, a scientific breakthrough, a product architecture, or a market opportunity. Farber adds a leadership requirement that is just as important. Innovators must understand how a technology will move through the systems that determine access. Coverage, payment, evidence expectations, payer behavior, and implementation capacity can decide whether a promising solution becomes part of care or remains outside the system.

Bashe frames the discussion through patient access and the practical role of policy in connecting innovation to physicians and patients. That framing gives the session its executive relevance. This is not a technical policy review. It is a conversation about how health leaders should think when the success of a treatment, device, platform, or care model depends on the alignment of science, evidence, payment, and delivery.

Policy strategy belongs next to product strategy. The organizations best positioned for the next stage of health innovation will be those that build evidence, reimbursement, regulatory, and adoption planning into the operating model early enough to shape the product, not merely support it after launch.

The Forces Shaping Health Innovation

Farber identifies a landscape shaped by program integrity, cost pressure, and technology expansion. Each force affects innovators in a different way. Program integrity protects the credibility of payment systems. Cost pressure raises the standard for evidence and value. Technology expansion creates openings for new treatments, AI-enabled tools, remote monitoring, digital platforms, and breakthrough devices that can demonstrate real-world benefit.

These forces are not separate. They interact directly in the decisions that determine whether new technologies can enter care, earn reimbursement, and support better outcomes. Leaders who understand only the science may miss the access challenge. Leaders who understand only reimbursement may miss the clinical opportunity. The strongest organizations will bring both perspectives together.

That focus creates an important opening for innovators, but it also places more responsibility on leadership teams. Companies need to show how their technologies work, how they improve outcomes, how they fit into care delivery, and how the payment model can support responsible adoption.

Responsible Oversight and Responsible Access

Program integrity is one of the most important themes in Farber’s analysis. Public programs need safeguards that protect patients, reduce inappropriate spending, and preserve trust in reimbursement systems. At the same time, the pursuit of integrity can slow responsible innovators when review processes become uncertain, overly broad, or difficult to navigate.

Farber’s point is not that oversight and innovation are in conflict by definition. His point is that the system must be designed carefully enough to support both. Health leaders need rules that protect patients and public resources while still allowing technologies with credible evidence and clear patient benefit to move forward.

That balance matters for CEOs, founders, investors, and health systems because uncertainty can delay investment and implementation. When innovators cannot see a viable path through review, payment, and adoption, patients may wait longer for tools that could improve care.

Cost Pressure and the Value Case for Innovation

Cost pressure changes the innovation equation. New technologies require research, development, evidence generation, regulatory work, implementation support, and payment models that recognize value. When reimbursement is too uncertain or too limited, companies may slow investment, and health systems may hesitate to adopt even promising solutions.

The leadership response is not to treat cost pressure as a barrier alone. It should become a discipline that pushes innovators to build stronger evidence, clearer value propositions, and more practical implementation pathways. The technologies best positioned for adoption will be those that demonstrate measurable improvement, support care teams, and fit into a sustainable payment environment.

Farber’s framing places value at the center of strategy. Innovation has to be clinically meaningful, operationally usable, financially credible, and connected to outcomes that matter to patients and the system.

CMMI and the Practical Pathway for New Models

CMMI is one of the most important mechanisms discussed in the session because it allows new approaches to care and payment to be tested in practice. Farber describes a period of experimentation around models that can support the use of new technologies and innovative approaches to treating disease.

For health innovators, this matters because models can create a more practical bridge between a technology’s promise and the evidence needed for adoption. They can define the environment in which a solution is used, measured, and paid for. That is especially relevant for AI-enabled tools, remote monitoring, digital health platforms, and disease-specific care models that need real-world pathways into clinical use.

The strategic question for companies is whether they can align their evidence strategy, technology design, patient population, and reimbursement plan with the kinds of models that can support adoption. The organizations that can do so will be better prepared to move from innovation claims to measurable value.

AHEAD and Outcome-Based Technology Adoption

Farber points to the AHEAD model as a development that health innovators should watch closely. He describes a model built around AI and remote monitoring technologies when they are connected to outcome-based enhanced payments in specific therapeutic areas. The model is important because it creates a pathway for companies that can show their technologies improve outcomes in defined patient populations.

The significance of AHEAD is not only the technology it may support. Its deeper importance is the connection between adoption and measurable results. Farber notes that participating manufacturers had to register as Medicare providers and that the payment levels were modest, but the structure gives companies a way to demonstrate improvement while entering a defined reimbursement environment.

For leaders, the message is direct. AI-enabled care models and remote monitoring platforms will be judged by evidence, outcomes, usability, and value. Technologies that can prove measurable benefit in a focused population will have a stronger path than technologies that rely only on broad claims about innovation.

RAPID and the Breakthrough Device Coverage Gap

RAPID addresses a familiar challenge for breakthrough medical device companies. FDA clearance or approval does not automatically lead to Medicare coverage, and that gap can slow access even after a product has moved through the regulatory review process.

Farber explains that RAPID is intended to improve coordination between device review and coverage for a larger number of breakthrough medical devices each year. He is appropriately cautious about execution because earlier efforts to synchronize these pathways have faced practical challenges. The leadership importance is clear. Faster review matters, but market access depends on whether coverage, evidence expectations, and payment pathways are aligned.

Device innovators should treat RAPID as part of a broader access strategy, not as a substitute for one. The companies most prepared to benefit will be those that can enter the process with strong evidence, clear clinical use cases, and a credible plan for adoption beyond initial coverage.

Medicare Signals and Payer Dynamics

Bashe raises a practical market access issue that health innovators know well. Medicare coverage can influence the broader payer environment, but private payers may not always follow the same path or move at the same speed. That dynamic is especially relevant for remote monitoring and remote therapeutic categories, where coverage patterns can diverge.

For innovators, the lesson is that payer strategy cannot be treated as a single event. Medicare coverage can be a meaningful signal, but companies still need evidence, payer communication, reimbursement planning, and a clear articulation of clinical and economic value. Coverage is not the end of the strategy. It is one stage in the movement from innovation to adoption.

Digital Tools and the Care Delivery Experience

Bashe brings the conversation back to the lived experience of healthcare delivery. The technologies now entering the system include smart embedded tools, wearables, remote monitoring, patient-provider communication platforms, and ambient documentation. Their value is not measured only by technical sophistication. Their value is measured by whether they reduce friction and support the relationship between clinicians and patients.

That perspective is essential for leaders building or adopting health technology. Digital tools should make care more connected, more usable, and more human. They should help clinicians spend less time fighting administrative burden and more time focused on patients.

The Leadership Agenda for Health Innovators

Farber’s closing guidance points to a clear leadership agenda. Health innovators need to understand not only whether a technology works, but how it will be evaluated, covered, paid for, adopted, and measured in practice. Strong science is the foundation, but the pathway to patient benefit also requires evidence strategies, reimbursement planning, regulatory readiness, payer engagement, and implementation models.

Outcomes sit at the center of that agenda. Companies need to show how their technologies improve care, support patient benefit, and fit within the systems that evaluate and finance adoption. That standard applies to digital health tools, AI-enabled models, remote monitoring platforms, breakthrough devices, and emerging scientific fields.

The companies that lead will be those that approach policy as a strategic capability rather than a late-stage obstacle. They will build product, evidence, payment, and implementation plans that reinforce one another and make it easier for the system to trust and adopt their innovations.

Patient Benefit as the Measure of Progress

Farber also points to frontier areas such as xenotransplantation, brain-computer interfaces, CRISPR-enabled advances, cloning-related breakthroughs, and other scientific innovations emerging from decades of research progress. These fields show why health policy matters so deeply. Transformative science needs regulatory expertise, evidence standards, payment pathways, implementation readiness, and public trust before it can become real patient benefit.

Bashe’s examples keep the discussion connected to the purpose of innovation. New tools should improve the care experience, support clinicians, and help patients stay connected to the healthcare system. Policy, payment, and evidence are not abstract structures. They are the mechanisms that determine whether better care can reach people faster and more responsibly.

The future of health innovation will favor organizations that build policy strategy into product strategy, demonstrate value through outcomes, and keep patient access at the center of every decision. The next generation of health leadership will belong to organizations that align scientific ambition with evidence, reimbursement discipline, implementation readiness, and an unwavering commitment to patient benefit.

Session Intelligence

Policy now functions as a core driver of health innovation strategy. Regulation, reimbursement, program integrity, evidence requirements, payer behavior, and outcome-based models shape whether new technologies can move from development to patient access.

Leadership Insight

Health innovation succeeds when science, evidence, payment, implementation, and patient benefit move together.

Execution Model

Innovators need early engagement with CMS, FDA, CMMI, payers, and reimbursement pathways while they build the evidence required for adoption.

Strategic Relevance

AI, remote monitoring, breakthrough devices, digital health tools, xenotransplantation, brain-computer interfaces, and other emerging technologies depend on frameworks that support responsible access and measurable outcomes.

Health Policy Regulating Innovation CMS FDA CMMI AHEAD Model RAPID Program Medicare Coverage Remote Monitoring AI in Healthcare Breakthrough Devices Patient Access Outcome-Based Models